Earnings summaries and quarterly performance for Crinetics Pharmaceuticals.
Executive leadership at Crinetics Pharmaceuticals.
R. Scott Struthers
Detailed
President and Chief Executive Officer
CEO
DP
Dana Pizzuti
Detailed
Chief Medical and Development Officer
IK
Isabel Kalofonos
Detailed
Chief Commercial Officer
JK
Jeff Knight
Detailed
Chief Operating Officer
SB
Stephen Betz
Detailed
Chief Scientific Officer
TS
Tobin Schilke
Detailed
Chief Financial Officer
Board of directors at Crinetics Pharmaceuticals.
Research analysts who have asked questions during Crinetics Pharmaceuticals earnings calls.
Catherine Novack
JonesTrading Institutional Services LLC
6 questions for CRNX
Also covers: ALDX, CAPR, DARE +3 more
Andy Chen
Wolfe Research, LLC
5 questions for CRNX
Also covers: ARGX, IMVT, INCY +7 more
DT
Douglas Tsao
H.C. Wainwright & Co.
5 questions for CRNX
Also covers: ALKS, APLS, ARGX +21 more
YR
Yasmeen Rahimi
Piper Sandler & Co.
5 questions for CRNX
Also covers: ALT, ARCT, CYTK +12 more
Cory Jubinville
LifeSci Capital
4 questions for CRNX
Also covers: LQDA, TARS
MS
Maxwell Skor
H.C. Wainwright & Co.
4 questions for CRNX
Also covers: ASND, AVIR, CYTK +4 more
Alex Thompson
Stifel Financial Corp.
3 questions for CRNX
Also covers: ARGX, ASND, IMVT +3 more
Brian Skorney
Robert W. Baird & Co.
3 questions for CRNX
Also covers: ABUS, BIIB, JAZZ +8 more
DL
David Lebowitz
Citigroup Inc.
3 questions for CRNX
Also covers: ALNY, ARWR, ASND +11 more
JF
Jessica Fye
JPMorgan Chase & Co.
3 questions for CRNX
Also covers: ALKS, ALNY, AMRN +23 more
JS
Joseph Schwartz
Oppenheimer
3 questions for CRNX
Also covers: ASND, AUPH, BMRN +14 more
TV
Tyler Van Buren
TD Cowen
3 questions for CRNX
Also covers: ADVM, ALLO, ARGX +13 more
DD
Dennis Ding
Jefferies Financial Group Inc.
2 questions for CRNX
Also covers: ARDX, CARA, FOLD +10 more
Gavin Clark-Gartner
Evercore ISI
2 questions for CRNX
Also covers: ACRS, ARGX, ASND +12 more
JS
Joe Schwartz
Leerink Partners
2 questions for CRNX
Also covers: BMRN, INSM, KALV +3 more
JW
Jon Wolleben
Citizen JMP
2 questions for CRNX
Also covers: BCRX, CLSD, MDGL +4 more
KD
Katherine Dellorusso
LifeSci Capital
2 questions for CRNX
Also covers: SLNO
LH
Luke Herrmann
Baird
2 questions for CRNX
Also covers: ALKS, CPRX, PTCT
Rohan Mathur
Oppenheimer & Co. Inc.
2 questions for CRNX
Also covers: CPRX, CYTK, VERU
YP
Yash Patel
Evercore ISI
2 questions for CRNX
Alexander Thompson
Stifel
1 question for CRNX
Also covers: ACRS, ARGX, ASND +5 more
AL
Anthea Li
Jefferies
1 question for CRNX
Also covers: ARDX, IMVT, PHAT +3 more
Catherine Okoukoni
Citizens JMP
1 question for CRNX
Also covers: ALT, KALV, MDGL +2 more
Charles Moore
Robert W. Baird & Co.
1 question for CRNX
Also covers: INKT
FD
Frances Dovell
TD Cowen
1 question for CRNX
Also covers: CELC, LNTH, TVTX
FD
Francis DiGiovanna
TD Securities
1 question for CRNX
GK
Gavin Kluck
Evercore ISI
1 question for CRNX
JF
Jessica Five
JPMorgan Chase & Co.
1 question for CRNX
Also covers: MRNA
JW
John Walden
Citizens JMP
1 question for CRNX
JW
John Wobel
Citizens JMP
1 question for CRNX
JS
Josh Schimmer
Cantor Fitzgerald
1 question for CRNX
Also covers: BBIO, BYSI, KRYS +5 more
KX
Katherine Xu
Citizens JMP
1 question for CRNX
LH
Lee Hung
Morgan Stanley
1 question for CRNX
Also covers: BLUE
LG
Leland Gershell
Oppenheimer & Co. Inc.
1 question for CRNX
Also covers: ARGX, ASND, CAPR +13 more
RL
Richard Law
Goldman Sachs
1 question for CRNX
Also covers: ARQT, MLYS
Will Scheibler
Leerink Partners
1 question for CRNX
YR
Yasim Rahimi
Piper Sandler Companies
1 question for CRNX
YD
Yuchen Ding
H.C. Wainwright & Co.
1 question for CRNX
Also covers: ABUS, ARDX, RYTM
Recent press releases and 8-K filings for CRNX.
Crinetics Pharmaceuticals Reports Q4 2025 Results, Provides 2026 Guidance, and Updates on PALSONIFY Launch and Pipeline
CRNX
Earnings
Product Launch
Guidance Update
- Crinetics Pharmaceuticals reported total net revenue of $6.2 million for Q4 2025, with $5.4 million from the U.S. commercial launch of PALSONIFY, contributing to a full-year 2025 total revenue of $7.7 million.
- The company ended 2025 with over $1 billion in cash equivalents and investments, which increased to approximately $1.4 billion after a January 2026 public offering, providing a runway to fund operations into 2030.
- For 2026, Crinetics expects GAAP operating expenses to be between $600 million and $650 million and non-GAAP operating expenses between $480 million and $520 million.
- The PALSONIFY launch saw more than 200 enrollment forms in Q4 2025 and received a positive CHMP opinion for its treatment in the EU.
- Key pipeline updates include ongoing Phase 3 studies for atumelnant in adult and pediatric CAH, a planned Phase 2/3 study for atumelnant in Cushing's disease, and a Phase 1/2 study for CRN09682 in SST2-expressing tumors.
6 days ago
Crinetics Pharmaceuticals Reports Q4 and Full-Year 2025 Results and Provides 2026 Outlook
CRNX
Earnings
Guidance Update
New Projects/Investments
- Crinetics Pharmaceuticals ended 2025 with $378.4 million in cash, cash equivalents, and short-term investments. The company also highlighted a $1.4 billion cash balance that funds its current operating plan and strategic initiatives into 2030.
- For the fourth quarter of 2025, net product revenue for PALSONIFY was $5.4 million, contributing to a full-year 2025 net product revenue of $11.1 million. The net loss for Q4 2025 was $40.9 million, and for the full year 2025, it was $147.1 million.
- The company expects its operating cash burn for 2026 to be between $140 million and $150 million.
- Key upcoming milestones include the initiation of the global Phase 2/3 study for Atumelnant in ADCS in 1H 2026 and continued commercial execution of PALSONIFY in the U.S..
6 days ago
Crinetics Pharmaceuticals Reports Q4 and Full Year 2025 Financial Results, Highlights PALSONIFY Launch and Pipeline Progress
CRNX
Earnings
Product Launch
Guidance Update
- Crinetics Pharmaceuticals reported $6.2 million in total net revenue for Q4 2025, including $5.4 million from PALSONIFY net product revenue, contributing to a full-year 2025 total revenue of $7.7 million.
- The company's first commercial product, PALSONIFY, saw more than 200 enrollment forms received in Q4 2025 and engaged over 125 unique prescribers, while also securing formulary wins and receiving a positive CHMP opinion for EU treatment.
- Crinetics ended 2025 with over $1 billion in cash, equivalents, and investments, which increased to approximately $1.4 billion after a January 2026 public offering.
- The company expects 2026 GAAP operating expenses to be between $600 million and $650 million, with existing cash and investments sufficient to fund operations into 2030.
- The pipeline is advancing with atumelnant in Phase 3 studies for CAH and a Phase 2/3 study for Cushing's disease initiated in H1 2026, and CRN09682 in a Phase 1/2 study for SST2-expressing tumors.
6 days ago
Crinetics Pharmaceuticals Reports Q4 and Full Year 2025 Financial Results and Provides Pipeline Updates
CRNX
Earnings
Product Launch
New Projects/Investments
- Crinetics Pharmaceuticals reported $6.2 million in total net revenue for Q4 2025, with $5.4 million from the U.S. launch of PALSONIFY, contributing to a full-year 2025 total revenue of $7.7 million.
- The company concluded 2025 with over $1 billion in cash and investments, which increased to approximately $1.4 billion following a January 2026 public offering, extending its operational runway into 2030. For 2026, GAAP operating expenses are projected to be between $600 million and $650 million.
- The PALSONIFY launch in Q4 2025 demonstrated strong uptake with more than 200 enrollment forms and over 125 unique prescribers, supported by favorable payer dynamics including 50% of claims pre-reimbursed.
- Pipeline advancements include ongoing Phase III studies for Atumelnant in CAH, the planned initiation of a global Phase II/III study for Atumelnant in Cushing's disease (ADCS) in H1 2026, and the dose escalation phase of a Phase I/II study for CRN09682 in SST2-expressing tumors.
6 days ago
Crinetics Pharmaceuticals Reports Q4 and Full Year 2025 Financial Results
CRNX
Earnings
Product Launch
Guidance Update
- Crinetics Pharmaceuticals reported $6.2 million in revenue for the fourth quarter of 2025 and $7.7 million for the full year 2025, with a net loss of $122.8 million for Q4 2025 and $465.3 million for the full year 2025.
- The company generated $5.4 million in net product revenue from the U.S. commercial launch of PALSONIFY™ (Paltusotine) in Q4 2025, following its FDA approval on September 25, 2025.
- As of December 31, 2025, Crinetics held $1.0 billion in cash, cash equivalents, and investment securities, which increased to approximately $1.4 billion after a public offering completed on January 8, 2026.
- Crinetics expects its 2026 GAAP operating expenses to range between $600 million to $650 million.
- The company announced a positive opinion from the European Medicines Agency (EMA) for PALSONIFY and plans to initiate a Phase 2/3 study of Atumelnant for ACTH-dependent Cushing's Syndrome in the first half of 2026.
6 days ago
Crinetics Initiates Pediatric Phase 2/3 Trial for Atumelnant in CAH
CRNX
New Projects/Investments
- Crinetics Pharmaceuticals, Inc. has dosed the first patient in its BALANCE-CAH Phase 2/3 trial evaluating investigational candidate atumelnant for the treatment of classic congenital adrenal hyperplasia (CAH) in children and adolescents.
- Atumelnant is a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist and is the first and only small molecule ACTH receptor antagonist in late-stage clinical development.
- The company recently received Orphan Drug Designation from the U.S. Food & Drug Administration for atumelnant in the treatment of classic CAH, and the BALANCE-CAH study is a potential registrational study.
Jan 22, 2026, 9:05 PM
Crinetics Pharmaceuticals, Inc. Provides Preliminary Q4 2025 Revenue and Business Update
CRNX
Earnings
Product Launch
New Projects/Investments
- Crinetics Pharmaceuticals, Inc. expects to report net product revenue from PALSONIFY (paltusotine) of over $5.0 million for the fourth quarter ended December 31, 2025. This estimate is preliminary and unaudited.
- As of January 8, 2026, the company reported approximately $1.4 billion in cash, cash equivalents, and investments.
- The company provided a business update at the J.P. Morgan Healthcare Conference, highlighting the early commercial success of PALSONIFY and the initiation of Phase 3 studies for Atumelnant in Congenital Adrenal Hyperplasia (CAH) and Carcinoid Syndrome (CS).
Jan 13, 2026, 10:02 PM
Crinetics Reports Strong Palsinify Launch and Pipeline Progress, Secured Funding Through 2030
CRNX
Product Launch
New Projects/Investments
- Crinetics Pharmaceuticals reported a successful launch of Palsinify for acromegaly, with over 200 patients enrolled and more than $5 million in revenue in 2025, and aims for it to become a blockbuster drug by expanding its prescriber base and activating patients.
- The company initiated Phase 3 studies for Paltusotine in carcinoid syndrome and Atumelnant in adult congenital adrenal hyperplasia (CAH), following positive Phase 2 data for Atumelnant showing dramatic reductions in biomarker A4.
- Crinetics is well-funded, with approximately $1.4 billion in the bank, providing a financial runway through 2030 and covering potential approvals for its pipeline products.
- A new compound, 9682, has entered Phase 1/2 studies for SST2-positive expressing solid tumors, expanding the company's pipeline.
Jan 13, 2026, 5:45 PM
Crinetics Pharmaceuticals reports strong 2025 performance and pipeline advancements
CRNX
Product Launch
New Projects/Investments
Guidance Update
- Crinetics Pharmaceuticals reported preliminary and unaudited ~$1.4 billion in cash, cash equivalents, and investments as of January 8, 2026, which is expected to fund operating plans well into 2030.
- The company launched PALSONIFY (paltusotine), achieving preliminary and unaudited >$5 million in net product revenue for 4Q2025.
- In 2025, Crinetics initiated Phase 3 studies for paltusotine in carcinoid syndrome (first patient randomized November 2025) and for atumelnant in adult congenital adrenal hyperplasia (CAH) (first patient randomized December 2025).
- A Phase 1/2 program for CRN09682 in neuroendocrine tumors (NETs) also commenced, with the first patient dosed in November 2025.
Jan 13, 2026, 5:45 PM
Crinetics Provides Business and Pipeline Updates at J.P. Morgan Healthcare Conference
CRNX
Product Launch
New Projects/Investments
Guidance Update
- Crinetics Pharmaceuticals reported Palsinify generated over $5 million in revenue in 2025, with more than 200 patients enrolled and over 125 unique prescribers in the last quarter.
- The company announced it is funded through 2030 with approximately $1.4 billion in the bank, which is expected to cover potential approvals for carcinoid syndrome, CAH, and atumelnant.
- Pipeline updates include the initiation of Phase 3 studies for paltusotine in carcinoid syndrome and atumelnant in adult CAH, as well as a Phase 1/2 study for 9682 in NETs.
- Crinetics aims to emerge as a premier endocrinology business by 2030, projecting two marketed products with four approved indications and seven additional clinical pipeline candidates.
Jan 13, 2026, 5:45 PM
Quarterly earnings call transcripts for Crinetics Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more